SCHEMBL8680487

SCHEMBL8680487

CC(=O)N1CCc2sccc2C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.57
HSP90AA1 P07900 3/20 0.53
PRMT5 O14744 2/20 0.44
WDR77 Q9BQA1 2/20 0.44
HHAT Q5VTY9 1/20 0.44
AKR1C3 P42330 1/20 0.43
CYP2C19 P33261 2/20 0.42
DRD1 P21728 2/20 0.42
THRB P10828 1/20 0.42
NR1I2 O75469 1/20 0.42
ABCB11 O95342 1/20 0.42
CHRM2 P08172 1/20 0.42
ADRA2A P08913 1/20 0.42
CYP2B6 P20813 1/20 0.42
HTR2A P28223 1/20 0.42
SLC6A4 P31645 1/20 0.42
OPRM1 P35372 1/20 0.42
OPRK1 P41145 1/20 0.42
HTR2B P41595 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10649424 0.86 NOTUM (0.57) NOTUMHSP90AA1PRMT5WDR77DRD1
SCHEMBL2023735 0.84 HSP90AA1 (0.51) HSP90AA1PRMT5WDR77HHATAKR1C3
SCHEMBL4253684 0.83 HSP90AA1 (0.50) HSP90AA1PRMT5WDR77AKR1C3CYP2C19
SCHEMBL19722818 0.83 HSP90AA1 (0.50) HSP90AA1PRMT5WDR77AKR1C3CYP2C19
SCHEMBL2962273 0.83 HSP90AA1 (0.50) HSP90AA1PRMT5WDR77AKR1C3CYP2C19
SCHEMBL16219051 0.82 HSP90AA1 (0.56) HSP90AA1PRMT5WDR77AKR1C3CYP2C19
SCHEMBL19296215 0.82 HSP90AA1 (0.50) HSP90AA1PRMT5WDR77AKR1C3CYP2C19
SCHEMBL8917620 0.80 NOTUM (0.46) NOTUMHSP90AA1PRMT5WDR77HHAT
SCHEMBL21411295 0.79 KEAP1 (0.52) HSP90AA1PRMT5WDR77CYP2C19SLC6A4
SCHEMBL22481607 0.79 HSP90AA1 (0.47) HSP90AA1PRMT5WDR77AKR1C3CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339591-A1 COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING A DEMENTIA GLIAPHARM SA (CH) 2020-10-29 US disclosed
US-20200325148-A1 COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING MOTOR NEURON DISEASES GLIAPHARM SA (CH) 2020-10-15 US disclosed
WO-2020132378-A2 COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING DEPRESSION GLIAPHARM SA (CH) 2020-06-25 WO disclosed
EP-2780337-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS MERCK SHARP & DOHME (US) 2017-12-20 EP disclosed
US-9018224-B2 Substituted cyclopropyl compounds useful as GPR119 agonists MERCK SHARP & DOHME CORP. (US) 2015-04-28 US disclosed
US-20140329798-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS MERCK SHARP & DOHME LLC 2014-11-06 US disclosed
WO-2013074388-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS MERCK SHARP & DOHME CORP. (US) 2013-05-23 WO disclosed
US-7160877-B2 Aliphatic nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. (JP) 2007-01-09 US disclosed
EP-0542411-B1 TETRAHYDROTHIENOPYRIDINE DERIVATIVES, FURO AND PYRROLO ANALOGS THEREOF AND THEIR PREPARATION AND USES FOR INHIBITING BLOOD PLATELET AGGREGATION SANKYO CO (JP) 1998-08-12 EP disclosed
US-5691330-A ANTIPSYCHOTIC AGENT YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-11-25 US disclosed
US-5532240-A ANTIPSYCHOTIC AGENTS AND ANTISEROTONIN AGENTS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1996-07-02 US disclosed
US-5436242-A Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation SANKYO COMPANY, LIMITED (JP) 1995-07-25 US disclosed
EP-0596125-A1 CONDENSED THIOPHENE COMPOUND AND PHARMACEUTICAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-05-11 EP disclosed
US-5288726-A Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation UBE INDUSTRIES LIMITED (JP) 1994-02-22 US disclosed
EP-0542411-A2 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation Sankyo Company Limited (JP) 1993-05-19 EP disclosed
US-4193997-A ANTICOAGULANT, HTROMBOSIS, ANALGESICS, ANTIINFLAMMATORY PARCOR (FR) 1980-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339591-A1 COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING A DEMENTIA ACHE, PSEN2, PSEN1 NOTUM 2689/4885HSP90AA1 821/4885PRMT5 167/4885
US-20200325148-A1 COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING MOTOR NEURON DISEASES SMN1; SMN2, NLN, PMP22 NOTUM 3665/4885HSP90AA1 950/4885PRMT5 993/4885
US-20140329798-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS GPR119, GPR27, GCGR NOTUM 3650/4885HSP90AA1 2486/4885PRMT5 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.